283. Acquired pure red cell aplasia Clinical trials / Disease details
Clinical trials : 19 / Drugs : 36 - (DrugBank : 23) / Drug target genes : 20 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001962 (ClinicalTrials.gov) | November 1999 | 18/1/2000 | A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure | A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia | Aplastic Anemia;Pure Red Cell Aplasia;Diamond Blackfan Anemia | Drug: Daclizumab | Neal Young, M.D. | NULL | Terminated | 2 Years | N/A | All | 100 | Phase 2 | United States |